Research Analysts Offer Predictions for HOWL FY2024 Earnings

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Leerink Partnrs increased their FY2024 EPS estimates for shares of Werewolf Therapeutics in a note issued to investors on Monday, November 11th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($1.98) per share for the year, up from their prior estimate of ($2.07). The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.62) per share. Leerink Partnrs also issued estimates for Werewolf Therapeutics’ Q4 2024 earnings at ($0.80) EPS, Q1 2025 earnings at ($1.17) EPS, Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($4.15) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($2.98) EPS and FY2028 earnings at ($2.56) EPS.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $2.15 on Wednesday. Werewolf Therapeutics has a twelve month low of $1.66 and a twelve month high of $8.19. The business’s 50 day moving average price is $2.27 and its two-hundred day moving average price is $2.93. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its stake in shares of Werewolf Therapeutics by 96.4% during the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after buying an additional 544,881 shares during the last quarter. Janus Henderson Group PLC bought a new position in Werewolf Therapeutics in the 1st quarter valued at about $10,922,000. Acadian Asset Management LLC lifted its position in Werewolf Therapeutics by 119.8% during the first quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after acquiring an additional 94,212 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Werewolf Therapeutics by 26.8% during the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after acquiring an additional 233,909 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after purchasing an additional 86,800 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.